Pancreatic Cancer Research

ResearcherWest Virginia UniversityActive in the last 2 years

Naomi H. Fei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9278-3521; OpenAlex author ID A5069588948. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 8

  1. Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey. Co-author DOI 10.1002/cncr.70446↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma-Past, Present, and Future. Co-author DOI 10.3390/cancers18172754↗
  4. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2024.103375↗
  5. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  6. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. Co-author DOI 10.1136/jitc-2021-004485↗
  7. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  8. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pashtoon Murtaza Kasi · 3 shared papers, 2022–2026 · strength 0.49
  2. Chandrikha Chandrasekharan · 2 shared papers, 2024–2026 · strength 0.43
  3. Andy Tran · 1 shared paper, 2026 · strength 0.43
  4. Tejeshwar Jain · 1 shared paper, 2026 · strength 0.43
  5. Vikas Dudeja · 1 shared paper, 2026 · strength 0.43
  6. Timothy J. Brown · 1 shared paper, 2026 · strength 0.27
  7. Udhayvir Singh Grewal · 1 shared paper, 2026 · strength 0.27
  8. Kawther Abdilleh · 1 shared paper, 2026 · strength 0.27
  9. Melissa Ellen Hogg · 2 shared papers, 2020–2021 · strength 0.24
  10. Amer H. Zureikat · 2 shared papers, 2020–2021 · strength 0.24
  11. Herbert J. Zeh · 2 shared papers, 2020–2021 · strength 0.24
  12. Nathan Bahary · 2 shared papers, 2020–2021 · strength 0.24
  13. Brian A. Boone · 2 shared papers, 2020–2021 · strength 0.24
  14. Michael T. Lotze · 2 shared papers, 2020–2021 · strength 0.24
  15. Aatur Dilip Singhi · 2 shared papers, 2020–2021 · strength 0.24
  16. Harshabad Singh · 1 shared paper, 2026 · strength 0.19
  17. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.19
  18. Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.19
  19. Alexis Diane Leal · 1 shared paper, 2026 · strength 0.19
  20. Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.19
  21. Craig Devoe · 1 shared paper, 2026 · strength 0.19
  22. Syed Mohammad Ali Kazmi · 1 shared paper, 2026 · strength 0.19
  23. Jonathan D. Mizrahi · 1 shared paper, 2026 · strength 0.19
  24. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.19
  25. Ben George · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.